An Official Website of the United States Government
Company Information:
Name:
TUNITAS THERAPEUTICS, INC.
Address:
409 Illinois Street
San Francisco, CA 94158-2509
San Francisco, CA 94158-2509
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Cat allergen-human Fc-gamma1 chimeric proteins to treat cat allergy
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Nolan Sigal
Award Amount:
$300,000.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this SBIR proposal is to develop and commercialize a new approach for allergen specific immunotherapy as treatment for cat allergy. This proposal will provide a novel therapeutic for a very importan
t inhalant allergen and serve as a model… More
Allergen???Fc-gamma1 proteins to treat food allergy
Award Year / Program / Phase:
2010 / STTR / Phase I
Agency:
HHS
Research Institution:
University Of California Los Angeles
Abstract:
DESCRIPTION (provided by applicant): The goal of this proposal is to develop and commercialize a novel approach for allergen specific immunotherapy as treatment for severe food allergy. Food allergy affects about 3.5% of the US population and 6% to 8% ofyoung children. It is clearly on the rise.… More
A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma
Award Year / Program / Phase:
2011 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Nolan Sigal – 650-887-4747
Award Amount:
$443,494.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop and commercialize a novel biologic therapy for the treatment of allergic disease and particularly allergic asthma. Specifically, this proposal will provide the critical immunogenicity, mechanistic and biomarker data… More
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Nolan Sigal – 650-887-4747
Award Amount:
$3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to develop and commercialize a novel biologic for allergen- specific immunotherapy as effective treatment for cat allergy/asthma. Cat allergy is common, with 17% of USpopulation, age 6-59, being skin test… More
Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy
Award Year / Program / Phase:
2012 / STTR / Phase II
Agency:
HHS
Research Institution:
UNIVERSITY OF CALIFORNIA LOS ANGELES
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this Phase 2 STTR is to develop and commercialize a novel approach for allergen specific immunotherapy as a treatment for severe food allergy. Currently treatment to prevent severe food reactions isa major unmet need. There is no effective… More